ARCHIVES

Phase III Regorafenib Trial Meets PFS Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

Acceptance Of Sentinel Node Biopsy Is Growing, Study Finds

October 31, 2003

Denosumab Demonstrates Superiority Over Zometa For Bone Metastases

August 28, 2009

Senate Approves $47 Million For More AIDs Drugs

September 19, 1986

A Patchwork Of Policies Emerges As Insurers Tighten Payments For ESAs.

March 30, 2007

Report Urges Better Working Conditions For Postdocs.

October 6, 2000

SWOG Trial Reports Longest Survival To Date For NSCLC

June 29, 2001